Compare Cytokinetics Inc (CYTK) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Cytokinetics Inc trades at $76.58 (market cap $10.63B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.16. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | VOOG | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $85.42 |
52-Week Low | $34.31 | $65.32 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
VOOG trades at $85.18, down slightly by 0.02% today. Technical indicators show a bullish trend with moving averages supporting upside momentum, though the relative strength index suggests potential overbought conditions near-term. Recent news highlights institutional accumulation, including Apella Capital increasing holdings by 463.2% as of August 2026, and the ETF hitting a new 52-week high, reflecting strong investor interest in large-cap growth exposure.
The outlook remains positive given the ETF's low expense ratio of 0.07% and focus on S&P 500 growth stocks, but risks include high concentration in technology sectors and sensitivity to market volatility. Continued institutional inflows and bullish technical signals support further gains, though overbought levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
